Continue to learn
since 2016
Maxvax Biotechnology was founded by Dr. Dexiang Chen in 2016 in China's south-western city ofChengdu. We are a fully integrated biotech dedicated to the development andcommercialization of safe and effective immunotherapies to combat current andemerging global health threats utilizing our adjuvant, recombinant protein andmRNA technology platforms. Maxvax has five subsidiaries with over 300 employeesand has been recognized as a national high-tech enterprise and a new "smallgiant" enterprise in Sichuan, and has been selected into the GEI China(potential) unicorn enterprise list.
Ourmission is to improve global public health through the development ofinnovative vaccines and immunotherapies to prevent and treat infectiousdiseases and cancer.
Togetherwith our team and global collaborators, Maxvax has developed a diverse pipelineconsisting of both prophylactic and therapeutic vaccines that targets some ofthe most prevalent diseases and global health threats with a focus oninfectious disease, allergies, and cancer. Our pipeline products are at variousstages of development with two candidates currently in the clinic.
Maxvax isbacked by some of the top global venture capitals and investment firms and aimto be a global health player.
Vision
Sense of Worth
Idea